Grados Aurélie, Ebbo Mikael, Bernit Emmanuelle, Veit Véronique, Mazodier Karin, Jean Rodolphe, Coso Diane, Aurran-Schleinitz Thérèse, Broussais Florence, Bouabdallah Reda, Gravis Gwenaelle, Goncalves Anthony, Giovaninni Marc, Sève Pascal, Chetaille Bruno, Gavet-Bongo Florence, Weitten Thierry, Pavic Michel, Harlé Jean-Robert, Schleinitz Nicolas
From the Department of Internal Medicine, CHU Timone, Assistance Publique-Hôpitaux de Marseille, Marseille (AG, ME, EB, VV, J-RH, NS); Department of Internal Medicine, CHU Conception, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille Université, Marseille (KM, RJ); Department of Hematology, Paoli Calmette Institute, Marseille (DC, TA-S, FB, RB); Department of Oncology, Paoli Calmette Institute, Marseille (GG, AG, MG); Department of Internal Medicine, Croix-Rousse Hospital, Lyon (PS); Department of Pathology, Paoli Calmette Institute, Marseille (BC); Department of Internal Medicine, Alpes du Sud Hospital, Gap (FG-B, TW); and Department of Oncology, Desgenettes Hospital, Lyon (MP), France.
Medicine (Baltimore). 2015 Jul;94(28):e928. doi: 10.1097/MD.0000000000000928.
The association between cancer and sarcoidosis is controversial. Some epidemiological studies show an increase of the incidence of cancer in patients with sarcoidosis but only few cases of sarcoidosis following cancer treatment have been reported. We conducted a retrospective case study from internal medicine and oncology departments for patients presenting sarcoidosis after solid cancer treatment. We also performed a literature review to search for patients who developed sarcoidosis after solid cancer. We describe the clinical, biological, and radiological characteristics and outcome of these patients. Twelve patients were included in our study. Various cancers were observed with a predominance of breast cancer. Development of sarcoidosis appeared in the 3 years following cancer and was asymptomatic in half of the patients. The disease was frequently identified after a follow-up positron emission tomography computerized tomography evaluation. Various manifestations were observed but all patients presented lymph node involvement. Half of the patients required systemic therapy. With a median follow-up of 73 months, no patient developed cancer relapse. Review of the literature identified 61 other patients for which the characteristics of both solid cancer and sarcoidosis were similar to those observed in our series. This report demonstrates that sarcoidosis must be considered in the differential diagnosis of patients with a history of malignancy who have developed lymphadenopathy or other lesions on positron emission tomography computerized tomography. Histological confirmation of cancer relapse is mandatory in order to avoid unjustified treatments. This association should be consider as a protective factor against cancer relapse.
癌症与结节病之间的关联存在争议。一些流行病学研究表明,结节病患者的癌症发病率有所上升,但仅有少数癌症治疗后发生结节病的病例报道。我们对内科和肿瘤科收治的实体癌治疗后出现结节病的患者进行了一项回顾性病例研究。我们还进行了文献综述,以查找实体癌后发生结节病的患者。我们描述了这些患者的临床、生物学和放射学特征及转归。我们的研究纳入了12例患者。观察到多种癌症,其中乳腺癌居多。结节病在癌症发生后的3年内出现,半数患者无症状。该疾病常在后续的正电子发射断层扫描计算机断层扫描评估后被发现。观察到多种表现,但所有患者均有淋巴结受累。半数患者需要全身治疗。中位随访73个月,无患者出现癌症复发。文献综述确定了另外61例患者,其实体癌和结节病的特征与我们系列研究中观察到的相似。本报告表明,对于有恶性肿瘤病史且在正电子发射断层扫描计算机断层扫描上出现淋巴结病或其他病变的患者,鉴别诊断时必须考虑结节病。为避免不合理治疗,癌症复发的组织学确认必不可少。这种关联应被视为预防癌症复发的保护因素。